ZLY18 is an experimental drug that acts as an agonist of the free fatty acid receptor 1 (FFA1) and all three types of peroxisome proliferator-activated receptor (alpha, delta, and gamma). It is in development for the treatment of non-alcoholic fatty liver disease.

References